Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Captain Jack who wrote (5187)	8/19/1998 4:00:00 PM
From: margie	Read Replies (5) of 6136

<<I DO NOT SEE THIS VOLUME/PRICE ACTION FROM 1 BUY RATING >> David Molowa, Bear Stearns analyst, initiated coverage of Agouron in June 1995 with a neutral, and I doubt if he ever rated it any higher. Molowa is a Vertex fan. For Molowa, a perennial bear on Agouron, to upgrade to a buy, with a price target of 50, or a price target of 100 if Remune is approved, is impressive. Bear Stearns does not do underwriting for Agouron, as far as I know. And the ten point drop has nothing to do with IR. Try the "Great Sustiva hype" and the emphasis on side effects of protease inhibitors. The side effects of NNRTI's have been ignored, and there are a lot more dropouts and side effects from NNRTI's than have been acknowledged. The book value of Agouron is $7.67, with 30.9 shares outstanding.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next